Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 3/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.54 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 2/20 | 0.53 |
| ▸ | PLAT | P00750 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018099 | 0.89 | PLAU (0.61) | P2RX1PTGS1P2RX7P2RX4TMPRSS4 | |
| SCHEMBL3034652 | 0.83 | MLYCD (0.57) | MEN1KMT2A | |
| SCHEMBL3023775 | 0.81 | MAOB (0.48) | PLAUPLATMEN1KMT2APLG | |
| SCHEMBL3028833 | 0.80 | KDM4E (0.64) | RXFP1MAPTPLAUPLATMEN1 | |
| SCHEMBL3278020 | 0.79 | P2RX1 (0.68) | P2RX1P2RX7P2RX4TMPRSS4PLAU | |
| SCHEMBL16670141 | 0.78 | HTT (0.69) | P2RX1PTGS1RXFP1MAPTMEN1 | |
| SCHEMBL29561761 | 0.78 | HTT (0.69) | P2RX1PTGS1RXFP1MAPTMEN1 | |
| SCHEMBL3028544 | 0.77 | PLAU (0.55) | PLAUPLATMEN1KMT2A | |
| SCHEMBL4476633 | 0.76 | MAPT (0.86) | P2RX1PTGS1RXFP1MAPTPLAU | |
| SCHEMBL7182329 | 0.75 | MAPT (0.63) | P2RX1PTGS1RXFP1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | claimed |
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | BRDT, AADAC, ACIN1 | P2RX1 3097/4885PTGS1 453/4885RXFP1 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.